Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9989339 | 0.74 | POLB (0.47) | POLBALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL2177129 | 0.72 | POLB (0.58) | POLBALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL14246067 | 0.72 | POLB (0.58) | POLBALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL26263884 | 0.72 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2LMNAMAOBKMT2A | |
| SCHEMBL684410 | 0.71 | CYP1A2 (0.42) | POLBHDAC3HDAC1HDAC2CYP1A2 | |
| SCHEMBL20102 | 0.71 | CES2 (0.62) | SMN1; SMN2LMNAMAOBKMT2A | |
| SCHEMBL17187852 | 0.71 | CES2 (0.62) | SMN1; SMN2LMNAMAOBKMT2A | |
| SCHEMBL12321300 | 0.70 | HDAC6 (0.50) | HDAC3HDAC1HDAC2MCHR1 | |
| SCHEMBL12410231 | 0.70 | SIGMAR1 (0.61) | POLBALDH1A1SMN1; SMN2LMNACYP1A2 | |
| SCHEMBL680730 | 0.69 | POLB (0.42) | POLBHDAC3HDAC1HDAC2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA (SE) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | POLB 1912/4885HDAC3 3727/4885HDAC1 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.